SCHEMBL24316738

SCHEMBL24316738

Cn1nnc(-c2cc3c(cc2C(F)F)NCCC3)n1

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CREBBP Q92793 8/20 0.33
▸ KDM4E B2RXH2 2/20 0.32
▸ MAPT P10636 2/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ THRB P10828 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ CASP1 P29466 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ CASP7 P55210 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ BRD4 O60885 1/20 0.31
▸ EP300 Q09472 1/20 0.31
▸ P4HB P07237 1/20 0.31
▸ ATM Q13315 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31496232 0.77 MAPT (0.38) CREBBPKDM4EMAPTALDH1A1LMNA
SCHEMBL29403112 0.75 CREBBP (0.50) CREBBPBRD4EP300
SCHEMBL17785637 0.75 CREBBP (0.50) CREBBPBRD4EP300
SCHEMBL27183574 0.71 CREBBP (0.33) CREBBPKDM4EMAPTALDH1A1LMNA
SCHEMBL30790215 0.71 CREBBP (0.33) CREBBPKDM4EMAPTALDH1A1LMNA
SCHEMBL30853471 0.71 MAPT (0.35) CREBBPKDM4EMAPTALDH1A1LMNA
SCHEMBL23930147 0.71 MAPT (0.35) CREBBPKDM4EMAPTALDH1A1LMNA
SCHEMBL17794991 0.71 GAA (0.36) CREBBPKDM4EMAPTALDH1A1LMNA
SCHEMBL21240848 0.71 ATM (0.34) KDM4EMAPTALDH1A1LMNATP53
SCHEMBL24316747 0.70 ATM (0.34) CREBBPKDM4EMAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-10-12 — — US disclosed
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-10-12 — — US disclosed
WO-2022053967-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2022-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS EP300, HDAC1, BRD3 CREBBP 5/4885KDM4E 472/4885MAPT 1105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback